Non-invasive systemic regenerative support in Istanbul
Stem cell therapy for heart failure in Istanbul
Led by Uzm. Dr. Cihan Bolat, our medical team evaluates your echocardiograms, cardiology reports, and clinical history to design a personalized intravenous Wharton's jelly MSC and exosome protocol aimed at modulating myocardial inflammation and supporting vascular and metabolic function.
Understanding heart failure and our systemic regenerative approach
Chronic heart failure is far more than a mechanical pumping issue; inside the heart and vascular system, surviving cardiomyocytes are continuously strained by chronic low-grade myocardial inflammation, microvascular endothelial dysfunction, mitochondrial energy depletion, and progressive interstitial fibrosis that stiffens the ventricular walls. Over time, this persistent inflammatory and neurohormonal burden reduces coronary microcirculation and impairs peripheral skeletal muscle energetics, leaving patients with breathlessness on exertion, persistent fatigue, reduced exercise tolerance, and slower recovery from everyday activities.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated for their ability to support cardiovascular repair through systemic immunomodulatory, angiogenic, and anti-fibrotic paracrine signaling. Administered intravenously, WJ-MSCs interact with systemic immune networks to shift pro-inflammatory M1 macrophages toward reparative M2 phenotypes, expand regulatory T cells (Tregs), and lower circulating levels of cardiotoxic cytokines such as TNF-alpha, IL-1beta, and IL-6. Simultaneously, WJ-MSCs and their nanoscale exosomes release cardioprotective growth factors — including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and adrenomedullin — alongside regulatory microRNAs that travel directly through the coronary microvasculature to nourish stressed cardiomyocytes, stimulate capillary endothelial repair, improve nitric oxide bioavailability, and calm fibrotic extracellular matrix remodeling.
At our clinic in Istanbul, led by Uzm. Dr. Cihan Bolat, our medical team evaluates your echocardiograms, ejection fraction, NT-proBNP/BNP biomarkers, renal function, and medication list before proposing any treatment. For medically stable patients, we design a non-invasive, rate-controlled intravenous WJ-MSC and exosome protocol alongside your cardiologist-prescribed medications — aiming to support stronger physical stamina, healthier vascular function, reduced systemic inflammation, and improved daily quality of life.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the heart and vasculature — and how biologics help
Four interconnected biological processes drive myocardial and systemic strain in chronic heart failure. Our intravenous Wharton's jelly MSC and exosome protocols are designed to support repair signaling across each of these pathways.
Therapeutic objectives of our protocol
Our intravenous regenerative protocols are designed to complement — never replace — the guideline-directed heart failure medications and cardiac devices managed by your home cardiologist.
Modulating chronic systemic and myocardial pro-inflammatory cytokine cascades
Supporting microvascular endothelial function and pro-angiogenic paracrine signaling
Regulating pro-fibrotic fibroblast signaling and supporting healthier extracellular matrix balance
Reducing systemic oxidative stress and supporting cellular mitochondrial energetics
Supporting physical stamina, exercise tolerance, and daily quality of life alongside your ongoing cardiology care
Persistent activation of innate and adaptive immune pathways elevates circulating and myocardial TNF-alpha, IL-1beta, and IL-6, which directly depress cardiomyocyte contractility, trigger oxidative stress, and impair mitochondrial ATP generation in surviving heart muscle cells.
Intravenous WJ-MSCs and exosomes counter this inflammatory state by shifting macrophages from pro-inflammatory M1 to reparative M2 phenotypes and releasing IL-10, TSG-6, and IGF-1, helping shield viable cardiomyocytes from cytokine-induced stress and supporting cellular energy resilience.
In chronic heart failure, damage to the inner endothelial lining of small coronary vessels reduces nitric oxide production and causes capillary rarefaction, leaving viable myocardial segments under-perfused and oxygen-starved during physical exertion.
WJ-MSCs and their nanoscale exosomes deliver vascular endothelial growth factor (VEGF), angiopoietins, and pro-angiogenic microRNAs directly to the vascular endothelium, supporting capillary repair, healthier nitric oxide signaling, and improved microvascular blood flow.
Chronic mechanical and inflammatory stress activates cardiac fibroblasts into myofibroblasts that deposit dense, cross-linked collagen fibers between muscle cells, stiffening the ventricle and impairing both contraction and relaxation.
Paracrine hepatocyte growth factor (HGF) secreted by WJ-MSCs, together with anti-fibrotic exosomal microRNAs, helps downregulate TGF-beta/Smad fibroblast activation and modulate matrix metalloproteinase balance, supporting a more compliant extracellular matrix microenvironment.
Heart failure is a systemic syndrome in which circulating inflammatory mediators and oxidative stress impair peripheral vascular tone, renal microcirculation, and skeletal muscle mitochondrial function, driving severe exercise intolerance and daily exhaustion.
Systemic intravenous administration of WJ-MSCs and exosomes helps calm whole-body vascular inflammation and supports peripheral endothelial and mitochondrial signaling, helping patients build better physical stamina and recovery capacity.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological rationale
Targeting chronic myocardial inflammation, microvascular dysfunction, and fibrosis
Clinical cardiovascular research has established that chronic systemic and myocardial inflammation is a central driver of ventricular remodeling and functional decline in heart failure. Even when guideline-directed medications control blood pressure and fluid volume, persistent pro-inflammatory cytokines, capillary rarefaction, and fibroblast activation continue to starve viable but hibernating cardiomyocytes of oxygen and metabolic energy. Regenerative medicine targets these underlying biological stressors — aiming to calm inflammatory cytokine cascades, support coronary microvascular perfusion, and soften pro-fibrotic signaling so surviving myocardial tissue can perform more efficiently.
WJ-MSCs & exosomes
Systemic cellular immunomodulation paired with nanoscale cardioprotective exosomes
Wharton's jelly-derived MSCs and their purified exosomes work synergistically to support the cardiovascular system without requiring invasive heart surgery or cardiac catheterization. Intravenously infused WJ-MSCs modulate systemic innate and adaptive immunity, reprogramming inflammatory monocytes into reparative M2 macrophages and secreting systemic trophic factors (HGF, IGF-1, VEGF). Because nanoscale WJ-MSC exosomes (30–150 nm) pass effortlessly through the pulmonary circulation without first-pass cell trapping, they reach the coronary microcirculation directly to transfer anti-apoptotic, pro-angiogenic, and anti-fibrotic microRNAs into stressed cardiomyocytes, endothelial cells, and cardiac fibroblasts.
Individualized protocol
Non-invasive protocols calibrated to your ejection fraction and fluid balance
Every heart failure patient has a distinct cardiac profile defined by left ventricular ejection fraction (HFrEF or HFpEF), ischemic or non-ischemic etiology, NYHA functional class, and renal and fluid status. Our medical team thoroughly reviews your recent echocardiogram, laboratory panels, and current cardiology prescriptions to confirm that travel and treatment are safe and appropriate. We personalize the exact Wharton's jelly MSC count, exosome concentration, infusion volume, and slow administration rate around your hemodynamic stability, while you remain on all guideline-directed medications prescribed by your home cardiologist.
Our treatment approach & administration routes
Our four-part protocol approach for heart failure
When clinically appropriate for medically stable patients, our medical team designs a non-invasive systemic program centered on GMP-certified Wharton's jelly MSCs and exosomes.
01
Intravenous Wharton's Jelly MSC Infusion
Administered via carefully rate-controlled peripheral intravenous infusion, fresh GMP-certified Wharton's jelly-derived MSCs interact with systemic immune organs and vascular networks. Through dynamic paracrine signaling, they promote M2 macrophage polarization, expand regulatory T cells, lower circulating TNF-alpha and IL-6 levels, and release systemic cardioprotective and angiogenic mediators (HGF, VEGF, IGF-1).
Role in your protocolServes as the systemic immunomodulatory foundation of your protocol, with infusion volume and rate carefully tailored to your cardiac fluid balance and monitored by our medical team.
02
Intravenous WJ-MSC Exosome Administration
Wharton's jelly MSC-derived exosomes are nanoscale extracellular vesicles carrying cardioprotective microRNAs, angiogenic growth factors, and anti-fibrotic signaling proteins. Because these acellular vesicles traverse the lungs without pulmonary first-pass trapping, they circulate directly through the coronary capillary bed to deliver repair signals into cardiomyocytes, endothelial cells, and cardiac fibroblasts.
Role in your protocolProvides concentrated cardioprotective and endothelial vesicular signaling in a minimal fluid volume ideal for patients requiring careful hemodynamic management.
03
Combined MSC & Exosome Paracrine Support
Pairing intravenous WJ-MSCs with WJ-MSC-derived exosomes — alongside supportive metabolic or antioxidant infusions when included in an individualized systemic plan — unites sustained cellular immune regulation with immediate, systemic vesicular bioavailability to support both myocardial energetics and peripheral vascular resilience.
Role in your protocolScheduled across single or multi-day outpatient sessions depending on your clinical tolerance, ejection fraction, and individualized protocol design.
04
Individualized Cardiology Record Review & Monitoring
Every protocol begins with a thorough medical evaluation of your echocardiograms, natriuretic peptide levels (NT-proBNP/BNP), renal function, and medication stability, followed by continuous non-invasive vital sign, ECG, oxygen saturation, and fluid-status monitoring throughout your treatment in Istanbul.
Role in your protocolEnsures you remain safely on all prescribed heart-failure medications and are hemodynamically stable before, during, and after treatment.
What we aim to achieve
How biological repair signaling connects to your clinical goals
We focus on practical functional capacity, systemic wellbeing, and structured follow-up at 1, 3, and 6 months in coordination with the routine echocardiograms and lab checks performed by your home cardiologist.
01
Physical stamina, walking tolerance & NYHA symptom class
By calming systemic and myocardial pro-inflammatory cytokines and supporting microvascular endothelial perfusion, the protocol aims to improve oxygen delivery and cellular energetics in both heart and skeletal muscle. During follow-up, we track your daily walking distance, stair-climbing tolerance, breathlessness during routine tasks, and NYHA functional class.
02
Daily energy, recovery speed & quality of life
Chronic inflammatory burden and oxidative stress often leave heart failure patients exhausted after minimal exertion. As WJ-MSCs and exosomes support mitochondrial resilience and vascular homeostasis, we monitor patient-reported improvements in daytime vitality, sleep comfort, recovery after activity, and overall quality of life.
03
Cardiology imaging & biomarker follow-up with your physician
While paracrine cell and exosome therapy is designed to support viable myocardium and microvascular health rather than instantaneously erase established scar tissue, objective tracking remains central. Patients share follow-up echocardiogram reports, NT-proBNP/BNP trends, and inflammatory markers obtained through their home cardiologist at 1, 3, and 6 months.
Our medical team monitors blood pressure, heart rate, ECG rhythm, oxygen saturation, and fluid comfort throughout your rate-controlled infusions in Istanbul, providing full GMP laboratory certificates and structured remote follow-up after you return home.
How treatment is personalized
How our medical team evaluates your heart failure case
Contact us with your cardiology reports, recent echocardiogram, and medication list. Uzm. Dr. Cihan Bolat and our medical team evaluate your information to confirm you are stable for travel, design a personalized intravenous WJ-MSC and exosome protocol where clinically appropriate, and explain the proposed biologics, therapeutic objectives, and costs.
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Heart failure stem cell therapy cost in Istanbul
After reviewing your cardiology records, we provide a clear, itemized proposal covering your individualized intravenous Wharton's jelly MSC and exosome protocol, GMP laboratory quality documentation, clinical monitoring in Istanbul, and private airport and hotel transfers.
Our 2026 systemic MSC and exosome program planning range starts from $7,000–$18,000 depending on cell dosage, exosome concentration, and number of infusion sessions, confirmed after your free medical evaluation.
Total Wharton's jelly MSC cell count and MSC-derived exosome dosage tailored to your cardiac profile
Number of rate-controlled intravenous administration sessions and supportive infusions included in your plan
Physician oversight, non-invasive cardiac and vital-sign monitoring, and clinical stay requirements
GMP laboratory release certificates, VIP airport/hotel transfers, and structured 1, 3, and 6-month follow-up
How intravenous Wharton's jelly MSCs and exosomes provide systemic anti-inflammatory and paracrine vascular support without invasive cardiac catheterization.
02
How infusion volumes and rates are tailored to my ejection fraction, renal function, and fluid balance.
03
What functional and biological objectives our protocol aims to support alongside my cardiologist's prescribed medications.
04
My exact itemized treatment quote, stay timeline (typically 3–5 days), and post-treatment follow-up schedule.
Evidence & important considerations
Clinical evidence and important scientific context
Clinical trials in heart failure have examined both invasive catheter-based myocardial injections and systemic mesenchymal stromal cell approaches. We present key clinical trials transparently so patients understand how published studies interpret inflammatory and functional outcomes, and why regenerative therapy is offered as supportive biological care rather than a cure or replacement for cardiology care.
Randomized double-blind sham-controlled study, 565 people with HFrEF
Finding
While the primary recurrent heart-failure hospitalization endpoint was neutral, pre-specified and exploratory analyses noted signals regarding major cardiovascular events in patients with elevated systemic inflammation.
Limitation
Evaluated an invasive transendocardial catheter injection procedure rather than our clinic's non-invasive intravenous Wharton's jelly MSC and exosome protocols.
Reported acceptable procedural safety and exploratory signals in clinical events and quality-of-life scores without major changes in left ventricular scar size.
Limitation
Supports the scientific concept that MSCs act primarily through anti-inflammatory and paracrine mechanisms rather than regrowing bulk myocardial muscle.
No. We do not perform intracoronary catheter infusions or transendocardial surgical injections. Our protocols use non-invasive, rate-controlled intravenous infusions of GMP-certified Wharton's jelly MSCs and WJ-MSC-derived exosomes under close clinical monitoring.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
